C06再生醫療(細胞治療、基因治療、組織工程等)

Single Cell Technology (SCT) was established in 2008. We named our antibody discovery technology after the Greek word atheneum, meaning an institute for scientific learning. AbTheneum™ technology was independently developed by merging 8 different fields. SCT has been helping global pharmaceutical companies find sought-after antibodies against unusual or difficult drug targets since 2016.

SCT’s AbTheneum™ platform combines micro-fabrication, next generation DNA sequencing (NGS), molecular biology, mechanical engineering, and bioinformatics together with patents and trade secrets. Output from AbTheneum™ is displayed as a compendium of Big Data in what is called the Antibody Atlas™. Each study focused on a different target protein has its own proprietary Antibody Atlas™. AbTheneum™ has been used to isolate hundreds to thousands of antibodies against various immune-oncology drug targets as well as the spike protein of SARS-CoV-2 virus. Recent validation experiments showed SCT’s anti-spike antibodies are on par with or better than those developed by Regeneron or Eli Lilly in terms of neutralization potency.